Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preference of Auto-HHPG-19K vs HHPG-19K in Chemotherapy-Induced Neutropenia
NCT06254742Phase 3Withdrawn
- Sponsor
- Hengrui
- Start
- Feb 2024
- Primary completion
- Jul 2025
- Modality
- rProtein (Recombinant Protein), Biologic
01
Overview
Phase 3, randomised, open-label trial of mecapegfilgrastim in chemotherapy-induced neutropenia (CIN) (2 arms), sponsored by Hengrui. Primary endpoint: Preference ratio of patients for HHPG-19K and Auto-HHPG-19K. Planned start Feb 2024; status: withdrawn.
02
Drugs
mecapegfilgrastim
03
Conditions
chemotherapy-induced neutropenia (CIN)
Beyond the preview
Go deeper on NCT06254742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06254742.